Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Conditions
Other Urinary | Urinary Bladder
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy.
Approximately 140 patients are anticipated to be enrolled across approximately 50 sites from North America and Europe.
- Ages18 years and older
- GenderBoth
- Trial withImmunomedics, Inc.
- Start Date06/01/2022
- End Date06/30/2023
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Andrea Brennan
- Andrea Martelli
- Armand Russo, MD
- D. Barry Boyd, MD, MS
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Hari Deshpande, MD
- Harold Tara Jr, MD
- Jane Kanowitz, MD
- Jaykumar Thumar, MBBS, MD
- Joseph Kim, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Lynn Cochran
- Michael Cohenuram, MD
- Michael Hurwitz, PhD, MD
- Neal Fischbach, MD
- Pawan Karanam, MD
- Sarah Carlson
- Su Hsien Lim, MD
- Susan Rabinowe, MD
- Victor Chang, MD
- Vidya Brown
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Zia Rahman, MD
- Last Updated07/29/2022
- Study HIC#2000023211